US PTAB IP Litigation
8,722 annotated decisions
Page 94 of 364 · 8,722 total
patent mixed - some claims cancelled, some upheld · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· PGR2025-00063
Apple (as petitioner) secured a partial victory over Omni MedSci's wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while leaving 11 claims intact.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· PGR2025-00063
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· PGR2025-00064
Apple successfully challenged Omni MedSci’s wearable health‑monitoring patent. The PTAB affirmed the claim construction and held all 23 claims obvious over prior art. No further briefing was authorized.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· PGR2025-00063
Apple, on behalf of Samsung, has filed an IPR petition challenging Omni MedSci’s ’533 wearable health‑monitoring patent. The petition asserts that the claims are obvious over prior‑art references Lisogurski, Carlson, and Mannheimer and requests that the Board institute the review.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· PGR2025-00064
Apple (as petitioner) prevailed in IPR2020‑00175, with the PTAB finding all challenged claims of the ’299 wearable physiological‑monitoring patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01254
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition asserts that the claims are obvious over a suite of prior‑art references covering optical sensing, AI processing and cloud connectivity. Apple requests that the Board institute the trial and find all claims unpatentable.
patent · May 8, 2025
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
· IPR2025-01378
Samsung and Radian have reached a confidential settlement and jointly moved to terminate the inter partes review of U.S. Patent 11,347,657, arguing that the proceeding is at an early stage and termination serves public policy and efficiency.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01254
Apple (as petitioner) seeks to invalidate Omni MedSci’s ’533 wearable health‑monitoring patent, asserting that the claims are obvious over Lisogurski, Carlson, and Mannheimer. The petition requests the PTAB to institute an IPR and cancel the claims.
patent · May 8, 2025
Microsoft Corporation v.Dialect, LLC
· IPR2025-01352
A statistical study of 192 IPR final written decisions from 2021 shows that patents invalidated in IPR have far more prior‑art citations and often depend on new evidence such as expert testimony. The findings suggest that post‑grant challenges frequently introduce prior art outside the examiner’s original search scope.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01253
Apple’s IPR petition challenges Omni MedSci’s ’484 wearable health‑monitoring patent, asserting that all 23 claims are obvious over a combination of prior‑art references. The petition seeks institution and a finding of unpatentability.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01253
Samsung and Apple have filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts obviousness over Lisogurski, Carlson, and Mannheimer references and asks the Board to institute the review and cancel the claims.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01251
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition argues the claims are obvious over a combination of five prior‑art references and requests that the Board institute the trial.
patent terminated or settled · May 8, 2025
Microsoft Corporation v.Dialect, LLC
· IPR2025-01352
Microsoft and Dialect reached a confidential settlement, leading the PTAB to terminate the IPR before trial. The Board granted the joint motion and ordered the settlement to remain confidential.
patent terminated or settled · May 8, 2025
Microsoft Corporation v.Dialect, LLC
· IPR2025-01352
Microsoft and Dialect reached a settlement that resolves disputes over patent 8,620,659 and other patents, leading to a joint motion to terminate the inter partes review before the Board makes an institution decision.
patent · May 8, 2025
Microsoft Corporation v.Dialect, LLC
· IPR2025-01352
Microsoft and Dialect have jointly moved to keep their settlement agreement confidential, invoking trade‑secret protections under the CFR. The motion seeks Board‑only access and notification of any disclosure requests.
patent · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01251
Apple seeks to invalidate Omni MedSci’s wearable health‑monitor patent, arguing that all challenged claims are obvious over prior art. The petition requests the PTAB to institute an IPR and cancel the claims.
patent denied · May 8, 2025
Microsoft Corporation v.Dialect, LLC
· IPR2025-01352
The PTAB denied Microsoft’s petition for an inter partes review of five patents owned by Dialect, LLC, exercising discretion under 35 U.S.C. § 314(a). The Board cited the patents’ age, subsidiary ownership, and a parallel district court case as reasons to avoid duplication.
patent mixed - some claims cancelled, some upheld · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01254
Apple (as petitioner) prevailed on 12 of the 23 challenged claims of Omni MedSci’s wearable physiological monitoring patent, finding them obvious over multiple prior‑art references. The remaining claims were left unpatentable pending further proof.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01254
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01253
Apple’s IPR resulted in the Board finding all six challenged claims of Omni MedSci’s ’299 patent unpatentable as obvious over a combination of prior‑art references covering wearable optical sensing.
patent terminated or settled · May 8, 2025
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
· IPR2025-01376
Samsung Electronics and Radian Memory Systems settled their IPR dispute over patent 11307995 before trial. The Board granted the joint motion to terminate, ending the proceedings.
patent mixed - some claims cancelled, some upheld · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01253
The PTAB issued a Final Written Decision in IPR2021‑00453, finding claims 1,2,7 and 15‑23 of Omni MedSci’s wearable pulse‑oximeter patent unpatentable over prior art, while leaving the remaining claims intact.
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01252
Apple’s IPR against Omni MedSci’s wearable physiological measurement patent resulted in all challenged claims being held unpatentable. The Board found the claims obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
patent all challenged claims unpatentable · May 8, 2025
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
· IPR2025-01251
Apple’s inter‑partes review of Omni MedSci’s ’533 patent resulted in the PTAB finding all challenged claims unpatentable for obviousness over Lisogurski, Carlson, and Mannheimer.
